Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but
the antibody characteristics that contribute to efficacy remain poorly understood. This study …

While the induction of broadly neutralizing antibodies (bNAbs) is a major goal of HIV
vaccination strategies, there is mounting evidence to suggest that antibodies with Fc effector …

Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role
in the development of vaccines and antibody-based interventions. We report systemic and …

Antibodies are the primary correlate of protection for most licensed vaccines; however, their
mechanisms of protection may vary, ranging from physical blockade to clearance via the …

The ongoing pandemic of SARS-CoV-2 represents the third time in just two decades that a
novel coronavirus (CoV) with significant morbidity and mortality has begun to circulate among …

Convalescent plasma has emerged as a promising COVID-19 treatment. However, the
humoral factors that contribute to efficacy are poorly understood. This study functionally and …

Mpox virus (MPXV) caused a global outbreak in 2022. Although smallpox vaccines were
rapidly deployed to curb spread and disease among those at highest risk, breakthrough …

Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …

Background A longitudinal study was performed to determine the breadth, kinetics, and
correlations of systemic and mucosal antibody responses to severe acute respiratory syndrome …

SARS-CoV-2 (CoV2) antibody therapies, including COVID-19 convalescent plasma (CCP),
monoclonal antibodies, and hyperimmune globulin, are among the leading treatments for …